Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4663361 | 0.76 | KLK7 (0.52) | — | |
| SCHEMBL29056163 | 0.73 | AKR1C3 (0.38) | ALDH1A1TSHR | |
| SCHEMBL11030839 | 0.69 | SLC18A2 (0.40) | — | |
| SCHEMBL14548187 | 0.65 | FAAH (0.45) | — | |
| SCHEMBL7814243 | 0.64 | POLB (0.54) | POLBALDH1A1S1PR1S1PR5 | |
| SCHEMBL1643401 | 0.63 | MTNR1B (0.48) | MTNR1BPOLB | |
| SCHEMBL10994286 | 0.63 | ALDH1A1 (0.55) | ALDH1A1BLMHTR2AMEN1TSHR | |
| SCHEMBL1642186 | 0.62 | FASN (0.41) | ALDH1A1 | |
| SCHEMBL13150784 | 0.62 | MEN1 (0.64) | ALDH1A1BLMHTR2AMEN1TSHR | |
| SCHEMBL27109144 | 0.62 | KEAP1 (0.57) | POLBALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | claimed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | claimed |
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | disclosed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | BACE1, PSEN1, BACE2 | MTNR1B 873/4885POLB 1560/4885ALDH1A1 2826/4885 |
| US-20050119329-A1 | Tetronic and tetramic acids | BACE1, PSEN1, BACE2 | MTNR1B 873/4885POLB 1560/4885ALDH1A1 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.